Latest Content

Take a look at the long-term effects of stimulant medications on ADHD, specifically tolerance and its implications for treatment efficacy.

Digital therapeutics revolutionize health care by enhancing patient outcomes through technology and offering scalable, evidence-based treatments for various conditions.

Lipocine's LPCN 1154 shows promise in treating postpartum depression, with a favorable safety profile and potential for rapid relief.

Explore the unique benefits of Ingrezza, a VMAT2 inhibitor for tardive dyskinesia, and how it compares to other treatment options.

Discover how objective testing transforms ADHD diagnosis and treatment, enhancing accuracy and accessibility for adults in hybrid care settings.

At-home transcranial magnetic stimulation offers a safe, effective way to treat depression, enhancing access and reducing reliance on medications.

Jail diversion programs offer vital support for individuals with mental health and substance use disorders, promoting recovery and reducing recidivism.

Let's investigate the complexities of diagnosing and treating ADHD in older adults, highlighting its prevalence, comorbidities, and treatment challenges.

Tonmya, a groundbreaking fibromyalgia treatment, is now available in the US, offering hope for millions suffering from chronic pain.

AI can transform the tedious task of writing progress notes for psychiatrists, offering both efficiency and challenges in clinical practice.

Chatbots risk validating suicidal thoughts, highlighting the urgent need for ethical programming to prioritize user safety and human connection.

Explore the emerging field of spiritual psychiatry, addressing the intersection of mental health, ethics, and personal meaning in patient care.

Silo Pharma partners with Allucent to advance SPC-15, a novel treatment for PTSD, aiming for FDA approval and addressing unmet patient needs.